Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

Share Price is delayed by 15 minutes
Get Live Data
1.10    -0.05 (-4.55%)
Bid:
1.00
Ask:
1.10
Spread: 0.10 (10.00%)
Market Cap: £25.80m
PXS Live PriceLast checked at - London Stock Exchange

Intraday Provexis Share Chart

Fruitflow update

14 Feb 2012 07:00

RNS Number : 3384X
Provexis PLC
14 February 2012
 



14 February 2012

Provexis plc

 

FRUITFLOW® UPDATE

 

Provexis plc ("Provexis" or the "Company"), the life-science business that develops, licenses and markets scientifically-proven functional food and sports nutrition technologies, announces an update of progress with its proprietary and patented Fruitflow® heart health technology.

 

At the end of 2011 the bioavailability of a small-scale production run of Fruitflow® powder was verified in our laboratory in the University of Aberdeen. During January 2012 an industrial scale production of powder was successfully completed at a strategic manufacturing site. The production of Fruitflow® powder on an industrial scale is an important step in the development of the technology, given the commercial interest being shown by consumer healthcare brand owners for tablet and capsule formats of Fruitflow®. Our Alliance partner, DSM Nutritional Products ("DSM") is currently developing tablet and capsule powder formats to present to potential commercial clients.

 

At the interims the Company stated that Fruitflow® would contribute limited revenues in the second half of the financial year via revenues from the launch of regional consumer products using our existing Fruitflow® syrup format in the US, Europe and Asia-Pacific markets. The Alliance has seen revenues from these products in the second half of the financial year, and while they will not be material to the Company in the financial year, they are an important indicator that Fruitflow® is gaining acceptance in the market.

 

Much of the focus of the Alliance partners is on the commercialisation of the powder version of Fruitflow® and work is being carried out in conjunction with global brand owners to assess the potential of product launches in the dietary supplement sector in major global markets.

 

To facilitate the commercialisation of Fruitflow® powder the Alliance partners are undertaking intellectual property registration in several major markets.

 

Provexis has identified a potential application for Fruitflow® in the sports nutrition market and has developed a product for its Science in Sport business. This product will launch in the UK in late summer, as part of a wider new product launch programme for the business.

 

ends-

 

For further information please contact:

 

Provexis plc

Stephen Moon, Chief Executive Tel: 01753 861777

 

Cenkos Securities plc

Stephen Keys Tel: 020 7397 8900

 

Haggie Financial LLP

Matthew Longbottom / Peter Rigby Tel: 020 7417 8989

matthew.longbottom@haggie.co.uk

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RESGGUWAPUPPGQW
Date   Source Headline
31st Jul 20127:00 amRNSFinal Results
27th Jul 20127:00 amRNSNotice of Results
31st May 20127:00 amRNSTotal Voting Rights
17th May 20127:00 amRNSDraw Down of Funds and Issue of Equity
24th Apr 20127:00 amRNSScience in Sport brand relaunch
23rd Apr 20124:31 pmRNSAdditional Listing
2nd Apr 20127:00 amRNSDirectorate Change
30th Mar 201211:46 amRNSTotal Voting Rights Update
30th Mar 20127:00 amRNSPre-Close Update
16th Mar 20124:35 pmRNSPrice Monitoring Extension
12th Mar 20124:40 pmRNSSecond Price Monitoring Extn
12th Mar 20124:35 pmRNSPrice Monitoring Extension
12th Mar 20127:00 amRNSScience in Sport Update
14th Feb 20127:00 amRNSFruitflow update
9th Jan 20124:40 pmRNSSecond Price Monitoring Extn
9th Jan 20124:35 pmRNSPrice Monitoring Extension
9th Jan 20127:00 amRNSProvexis to fuel GB rowing team
7th Dec 20113:01 pmRNSAdditional Listing
1st Dec 20117:00 amRNSChange of adviser
1st Dec 20117:00 amRNSInterim Results
28th Nov 20117:00 amRNSNotice of Interim Results
8th Nov 20117:00 amRNSRenewal of £25 million Equity Financing Facility
24th Aug 20113:24 pmRNSResult of AGM
24th Aug 20117:00 amRNSAGM Statement
8th Aug 20114:40 pmRNSSecond Price Monitoring Extn
8th Aug 20114:35 pmRNSPrice Monitoring Extension
4th Aug 20114:40 pmRNSSecond Price Monitoring Extn
4th Aug 20114:35 pmRNSPrice Monitoring Extension
1st Aug 20115:22 pmRNSNotice of AGM
29th Jul 20117:00 amRNSTotal Voting Rights
26th Jul 20114:46 pmRNSResult of open offer
15th Jul 20114:35 pmRNSHolding(s) in Company
14th Jul 201110:44 amRNSHolding(s) in Company
12th Jul 20114:23 pmRNSHolding(s) in Company
12th Jul 20119:17 amRNSHolding(s) in Company
11th Jul 20111:42 pmRNSChange of Registered Office
5th Jul 20117:00 amRNSOpen Offer
30th Jun 20114:55 pmRNSHolding(s) in Company
30th Jun 20117:00 amRNSTotal Voting Rights
28th Jun 20113:34 pmRNSHolding(s) in Company
24th Jun 201112:08 pmRNSCompletion of the acquisition of SiS
20th Jun 20119:36 amRNSDirector Dealing
17th Jun 20114:15 pmRNSGrant of Options
17th Jun 20117:00 amRNSFinal Results
17th Jun 20117:00 amRNSAcquisition of Science in Sport Ltd
1st Jun 20117:00 amRNSUpdate on Crohn's disease trial
1st Jun 20117:00 amRNSAppointment of New Product Director
1st Jun 20117:00 amRNSSigning of Development Agreement
31st Mar 20117:00 amRNSPre-close update
28th Feb 20118:49 amRNSDevelopment Agreement - Replacement announcement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.